Moleculin Biotech, Inc. — Net Income by Fiscal Year
10 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/85915661-a3f0-467d-b9f9-3a1e12739df8/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $33.6M | 2025-01-01 – 2025-12-31 | evidence 0001437749-26-028835 |
| FY 2024 | $26.0M | 2024-01-01 – 2024-12-31 | evidence 0001437749-26-028835 |
| FY 2023 | $29.8M | 2023-01-01 – 2023-12-31 | evidence 0001437749-26-028835 |
| FY 2022 | $-29.0M | 2022-01-01 – 2022-12-31 | evidence 0001437749-23-007537 |
| FY 2021 | $-15.9M | 2021-01-01 – 2021-12-31 | evidence 0001437749-22-007103 |
| FY 2020 | $-17.4M | 2020-01-01 – 2020-12-31 | evidence 0001437749-21-006940 |
| FY 2019 | $-13.2M | 2019-01-01 – 2019-12-31 | evidence 0001659617-20-000066 |
| FY 2018 | $-11.9M | 2018-01-01 – 2018-12-31 | evidence 0001659617-19-000018 |
| FY 2017 | $-9.8M | 2017-01-01 – 2017-12-31 | evidence 0001659617-18-000027 |
| FY 2016 | $-3.9M | 2016-01-01 – 2016-12-31 | evidence 0001659617-18-000027 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Moleculin Biotech, Inc. — all facts · Revenue · Operating Income